Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer
Navid Sobhani,
Anna Ianza,
Alberto D’Angelo,
Giandomenico Roviello,
Fabiola Giudici,
Marina Bortul,
Fabrizio Zanconati,
Cristina Bottin,
Daniele Generali
Affiliations
Navid Sobhani
Department of Medical, Surgical & Health Sciences, University of Trieste, Cattinara Teaching Hospital, 34149 Trieste, Italy
Anna Ianza
Department of Medical, Surgery & Health Sciences, University of Trieste, 34129 Trieste, Italy
Alberto D’Angelo
Department of Medical, Surgical & Health Sciences, University of Trieste, Cattinara Teaching Hospital, 34149 Trieste, Italy
Giandomenico Roviello
Division of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture (PZ), 85028 Rionero, Italy
Fabiola Giudici
Department of Medical, Surgical & Health Sciences, University of Trieste, Cattinara Teaching Hospital, 34149 Trieste, Italy
Marina Bortul
Department of Medical, Surgical & Health Sciences, University of Trieste, Cattinara Teaching Hospital, 34149 Trieste, Italy
Fabrizio Zanconati
Department of Medical, Surgical & Health Sciences, University of Trieste, Cattinara Teaching Hospital, 34149 Trieste, Italy
Cristina Bottin
Department of Medical, Surgical & Health Sciences, University of Trieste, Cattinara Teaching Hospital, 34149 Trieste, Italy
Daniele Generali
Department of Medical, Surgery and Health Sciences, University of Trieste, 34129 Trieste, Italy; Breast Cancer Unit and Translational Research Unit, ASST Cremona, Viale Concordia 1, C.A.P. 26100 Cremona, Italy
Breast cancer (BC) is the most common malignancy and second only to lung cancer in terms of mortality in women. Despite the incredible progress made in this field, metastatic breast cancer has a poor prognosis. In an era of personalized medicine, there is an urgent need for better knowledge of the biology leading to the disease, which can lead to the design of increasingly accurate drugs against patients’ specific molecular aberrations. Among one of the actionable targets is the fibroblast growth factor receptor (FGFR) pathway, triggered by specific ligands. The Fibroblast Growth Factor Receptors/Fibroblast Growth Factors (FGFRs/FGFs) axis offers interesting molecular targets to be pursued in clinical development. This mini-review will focus on the current knowledge of FGFR mutations, which lead to tumor formation and summarizes the state-of-the-art therapeutic strategies for targeted treatments against the FGFRs/FGFs axis in the context of BC.
